Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations
Neoantigens derived from tumor-specific genetic mutations might be suitable targets for cancer immunotherapy because of their high immunogenicity. In the current study, we evaluated the immunogenicity of 10 driver mutations that are frequently expressed in various cancers using peripheral blood mono...
Main Authors: | Susumu Iiizumi, Junya Ohtake, Naoko Murakami, Taku Kouro, Mamoru Kawahara, Fumiko Isoda, Hiroshi Hamana, Hiroyuki Kishi, Norihiro Nakamura, Tetsuro Sasada |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/2/266 |
Similar Items
-
Structural basis for T cell recognition of cancer neoantigens and implications for predicting neoepitope immunogenicity
by: Roy A. Mariuzza, et al.
Published: (2023-11-01) -
Main Strategies for the Identification of Neoantigens
by: Alexander V. Gopanenko, et al.
Published: (2020-10-01) -
Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer
by: Belén Aparicio, et al.
Published: (2022-11-01) -
Enhancing cholangiocarcinoma immunotherapy with adoptive T cells targeting HLA-restricted neoantigen peptides derived from driver gene mutations
by: Aussara Panya, et al.
Published: (2023-12-01) -
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
by: Zhi Pang, et al.
Published: (2023-12-01)